[go: up one dir, main page]

AR084507A1 - Derivados de indazoliltriazol - Google Patents

Derivados de indazoliltriazol

Info

Publication number
AR084507A1
AR084507A1 ARP110104813A ARP110104813A AR084507A1 AR 084507 A1 AR084507 A1 AR 084507A1 AR P110104813 A ARP110104813 A AR P110104813A AR P110104813 A ARP110104813 A AR P110104813A AR 084507 A1 AR084507 A1 AR 084507A1
Authority
AR
Argentina
Prior art keywords
alkyl
hal
denotes
cycloalkyl
het1
Prior art date
Application number
ARP110104813A
Other languages
English (en)
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of AR084507A1 publication Critical patent/AR084507A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Compuestos de la fórmula (1) se usan para el tratamiento de inflamación y trastornos autoinmunes. Composición farmacéutica, proceso de preparación y uso como moduladores de interleuquina-IRAK.Reivindicación 1: Un compuesto de la formula (1) en donde Q denota Ar o Het; E denota -(CH2)mCO-, -(CH2)mSO2, -(CH2)mNHCO- o un enlace simple; R1 denota H, OH, NH-alquilo C1-6, O-alquilo C1-6, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, Cyc, Hal, Het1, O-Het1, CO-Het1, NH-Het1, CO-Ar1, O-Ar1, Ar1, NH-Ar1, -(CH2)qHet1, -CONH-(CH2)qHet1, -CONH-Het1, -(CH2)qO-Het1, -(CH2)qO-Ar1, -(CH2)qAr1, -CONH-(CH2)qAr1, -CONH-Ar1, -CONH-cicloalquilo C3-6, -(CH2)qHal, -(CH2)qCyC, CF3, -(CH2)sNH-(CH2)q-Het1, -(CH2)sNH-(CH2)q-Ar1, en donde NH-alquilo C1-6, O-alquilo C1-6, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6 puede estar sustituido con 1 a 3 grupos seleccionados, de modo independiente, de O-alquilo C1-3, OH, CONH2, NH2; R2 denota H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, Hal, CF3, con preferencia H; R3 denota Het1, Ar1, NRaRb, COOH, -(CH2)qHet1, -(CH2)qAr1, -(CH2)qNRaRb, -(CH2)qCOOH o alquilo C1-6, en donde 1 a 3 átomos de hidrógeno pueden estar reemplazados, de modo independiente, por OH o CF3; R4 denota H, alquilo C1-6, alquenilo C2-6, Hal; Ra denota H, alquilo C1-6 lineal, ramificado o cíclico; Rb denota H, Hetb, Arb, -CO-Hetb, -CO-Arb, un cicloalquilo C3-8 o un alquilo C1-6 lineal o ramificado, en donde 1 a 3 átomos de hidrógeno pueden estar reemplazados por Hetb, Arb, NH2, N(alquilo C1-6)2, NH(alquilo C1-6), N(alquilo C1-6)(cicloalquilo C3-8), NH(cicloalquilo C3-8), O(alquilo C1-6), CN, OH, CF3, Hal; n es 0, 1, 2, 3 ó 4; m es 0, 1, 2, 3 ó 4; q es 1, 2 ó 3; s es 0, 1, 2 ó 3; Hal denota Cl, Br, I, F, con preferencia Cl o F; Ar denota un grupo arileno monocíclico divalente o bicíclico fusionado que tiene 6 a 14 átomos de carbono, que también puede estar sustituido con 1 a 4 sustituyentes seleccionados de Hal, alquilo C1-6, -(CH2)mO-alquilo C1-6, CN, OH, NO2, CF3, -(CH2)mCOOH, -(CH2)mCOO-alquilo C1-6; Het denota un grupo heterocíclico insaturado, saturado o aromático monocíclico divalente o bicíclico fusionado que tiene 1 a 5 heteroátomos seleccionados de modo independiente de N, O, S y/o un grupo -C=O que también puede estar sustituido con 1 a 4 sustituyentes seleccionados de Hal, alquilo C1-6, -(CH2)mO-alquilo C1-6, CN, OH, NO2, CF3, -(CH2)mCOOH, -(CH2)mCOO-alquilo C1-6; Ar1 denota un anillo carbocíclico aromático monocíclico o bicíclico que tiene 6 a 14 átomos de carbono, que no está sustituido o que está monosustituido, disustituido o trisustituido con Hal, -CF3, -OCF3, -NO2, -CN, perfluoroalquilo, Hal, -CF3, -OCF3, -NO2, -CN, perfluoroalquilo, alquilo C1-6 lineal o ramificado, cicloalquilo, -OH, -O-alquilo C1-6, -COalquilo C1-6, -NH2, -COH, -COOH, -CONH2, un grupo Rb tales como -CH2O(alquilo C1-6), -SO2NRaRb o SO2(alquilo C1-6); Het1 denota un anillo heterocíclico saturado, insaturado o aromático monocíclico o bicíclico (fusionado, en puente o espiro) que tiene 1 a 4 heteroátomos seleccionados de modo independiente de N, O, S y/o un grupo CO, que no está sustituido o que está monosustituido, disustituido o trisustituido con Hal, -CF3, -OCF3, -NO2, -CN, perfluoroalquilo, alquilo C1-6 lineal o ramificado, cicloalquilo C3-8, -OH, -O-alquilo C1-6, -NH2, -N(alquilo C1-6)2, -COH, -COOH, -CONH2, -COalquilo C1-6, -NHCO(cicloalquilo C3-6), un grupo Rb tales como -SO2NRaRb o SO2(alquilo C1-6); Hetb denota un anillo heterocíclico saturado, insaturado o aromático monocíclico o bicíclico (fusionado o espiro) que tiene 1 a 4 heteroátomos seleccionados de modo independiente de N, O, S y/o un grupo CO, que no está sustituido o que está monosustituido, disustituido o trisustituido con Hal, -CF3, -OCF3, -NO2, CN, perfluoroalquilo, -OH, -O-alquilo C1-6, -NH2, -COH, -COOH, - CONH2 o con un alquilo C1-6 lineal o ramificado, en donde 1 a 3 átomos de hidrógeno pueden estar reemplazados por NH2, N(alquilo C1-6)2, NH(alquilo C1-6), N(alquilo C1-6)(cicloalquilo C3-8), NH(cicloalquilo C3-8), O(alquilo C1-6), CN, OH, CF3, Hal, cicloalquilo C3-8, o con un anillo heterocíclico de 4 a 8 miembros que contiene un heteroátomo seleccionado de O, S y N; Arb denota un anillo carbocíclico aromático monocíclico o bicíclico que tiene 6 a 14 átomos de carbono, que no está sustituido o que está monosustituido, disustituido o trisustituido con Hal, -CF3, -OCF3, -NO2, -CN, perfluoroalquilo, Hal, -CF3, -OCF3, -NO2, -CN, perfluoroalquilo, -OH, -O-alquilo C1-6, -NH2, -COH, -COOH, -CONH2 o con un alquilo C1-6 lineal o ramificado, en donde 1 a 3 átomos de hidrógeno pueden estar reemplazados por NH2, N(alquilo C1-6)2, NH(alquilo C1-6), N(alquilo C1-6)(cicloalquilo C3-8), NH(cicloalquilo C3-8), O(alquilo C1-6), CN, OH, CF3, Hal, cicloalquilo C3-8 o con un anillo heterocíclico de 4 a 8 miembros que contiene un heteroátomo seleccionado de O, S y N; Cyc denota un anillo carbocíclico saturado o insaturado que tiene 3 a 8 átomos de carbono, con preferencia 5 ó 6 átomos de carbono, en donde 1 a 5 átomos de H están reemplazados por Hal, -CF3, -OCF3, -NO2, -CN, perfluoroalquilo, Hal, -CF3, -OCF3, -NO2, -CN, perfluoroalquilo, alquilo C1-6 lineal o ramificado, cicloalquilo, -OH, -O-alquilo C1-6, -COalquilo C1-6, -NH2, -COH, -COOH, -CONH2, un grupo Rb tales como -CH2O(alquilo C1-6), -SO2NRaRb o SO2(alquilo C1-6); y sus derivados, solvatos, tautómeros, sales, hidratos y estereoisómeros farmacéuticamente aceptables, incluyendo sus mezclas en todas las proporciones.
ARP110104813A 2010-12-20 2011-12-20 Derivados de indazoliltriazol AR084507A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424890P 2010-12-20 2010-12-20
EP10195867 2010-12-20

Publications (1)

Publication Number Publication Date
AR084507A1 true AR084507A1 (es) 2013-05-22

Family

ID=43838132

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104813A AR084507A1 (es) 2010-12-20 2011-12-20 Derivados de indazoliltriazol

Country Status (23)

Country Link
US (1) US9073892B2 (es)
EP (1) EP2655357B1 (es)
JP (1) JP6007189B2 (es)
KR (1) KR101842098B1 (es)
CN (1) CN103429585B (es)
AR (1) AR084507A1 (es)
AU (1) AU2011347711B2 (es)
BR (2) BR112013015460B1 (es)
CA (1) CA2822166C (es)
EA (1) EA023544B1 (es)
ES (1) ES2592713T3 (es)
HR (1) HRP20161127T1 (es)
HU (1) HUE029617T2 (es)
IL (1) IL226912A (es)
LT (1) LT2655357T (es)
MX (1) MX2013007149A (es)
PL (1) PL2655357T3 (es)
PT (1) PT2655357T (es)
RS (1) RS55165B1 (es)
SG (1) SG191205A1 (es)
SI (1) SI2655357T1 (es)
WO (1) WO2012084704A1 (es)
ZA (1) ZA201305483B (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
US9643955B2 (en) 2012-12-20 2017-05-09 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-nitrile-4-substituted orexin receptor antagonists
WO2014099697A1 (en) * 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. 3-ester-4-substituted orexin receptor antagonists
SG11201506100XA (en) * 2013-02-07 2015-09-29 Merck Patent Gmbh Pyridazinone-amides derivatives
DK2953952T3 (en) * 2013-02-07 2017-08-28 Merck Patent Gmbh MACROCYCLIC PYRIDAZININE DERIVATIVES
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ抑制剤としての二環式複素環
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
CA2935880A1 (en) * 2014-01-10 2015-07-16 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
EP3466955B1 (en) 2014-01-13 2020-12-16 Aurigene Discovery Technologies Limited Method of preparing oxazolo[4,5-b]pyridine and thiazolo[4,5-b]pyridine derivatives as irak4 inhibitors for treating cancer
US9926330B2 (en) 2014-09-30 2018-03-27 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
WO2016053770A1 (en) * 2014-09-30 2016-04-07 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
EP3200789B1 (en) * 2014-09-30 2019-11-06 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
WO2016053771A1 (en) * 2014-09-30 2016-04-07 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
HRP20210433T1 (hr) 2015-04-22 2021-04-30 Rigel Pharmaceuticals, Inc. Spojevi pirazola i postupak za dobivanje i upotrebu spojeva
US20180289685A1 (en) 2015-04-30 2018-10-11 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
EP3195865A1 (de) 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Kombinationen von irak4 inhibitoren und btk inhibitoren
EP3423446B1 (de) 2016-03-03 2020-09-16 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
US10501437B2 (en) 2016-04-29 2019-12-10 Bayer Pharma Aktiengesellschaft Crystalline forms of N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
US10759758B2 (en) 2016-04-29 2020-09-01 Bayer Pharma Aktiengesellschaft Polymorphic form of N-{6-(hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
RU2743170C2 (ru) 2016-06-01 2021-02-15 Байер Энимал Хелс Гмбх Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
BR112019018991A2 (pt) 2017-03-31 2020-04-14 Aurigene Discovery Technologies Limited compostos e composições para tratar distúrbios hematológicos
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MX2020003190A (es) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
SG11202002475TA (en) 2017-10-19 2020-04-29 Bayer Animal Health Gmbh Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
EP4410377A3 (en) 2017-10-31 2024-11-13 Curis, Inc. Compounds and compositions for treating hematological disorders
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
CN119241541A (zh) 2018-05-04 2025-01-03 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
BR112021010484A2 (pt) 2018-11-30 2021-08-24 Kymera Therapeutics, Inc. Degradadores de irak e usos dos mesmos
ES3015269T3 (en) 2019-02-11 2025-04-30 Merck Patent Gmbh Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CA3145043A1 (en) * 2019-06-27 2020-12-30 Biogen Ma Inc. 2h-indazole derivatives and their use in the treatment of disease
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
BR112022003564A2 (pt) 2019-08-30 2022-05-17 Rigel Pharmaceuticals Inc Composto, composição, composição seca por pulverização, método de preparação de uma composição seca por pulverização e método
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR102782229B1 (ko) 2019-10-02 2025-03-20 (주)카이노스메드 N-(1h-이미다졸-2-일)벤즈아미드 화합물 및 활성 성분으로 이를 포함하는 약학 조성물
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114599652B (zh) * 2019-10-31 2024-07-12 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物
EP4061816A1 (en) 2019-11-19 2022-09-28 F. Hoffmann-La Roche AG Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
EP4069693B1 (en) 2019-12-03 2024-03-20 F. Hoffmann-La Roche AG Hydropyrido[1,2-alpha]pyrazine compounds for the treatment of autoimmune diseases
IL293001A (en) 2019-12-04 2022-07-01 Incyte Corp Derivatives of fgfr repressors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN115052627A (zh) 2019-12-17 2022-09-13 凯麦拉医疗公司 Irak降解剂和其用途
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
CN116867758A (zh) 2020-12-30 2023-10-10 凯麦拉医疗公司 Irak降解剂和其用途
AU2022220043A1 (en) 2021-02-15 2023-08-31 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
WO2022187303A1 (en) 2021-03-03 2022-09-09 Rigel Pharmaceuticals, Inc. A method for treating a disease or condition using a pyrazole compound or formulation thereof
US12178821B2 (en) 2021-04-08 2024-12-31 Curis, Inc. Combination therapies for the treatment of cancer
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
IL308314A (en) 2021-05-07 2024-01-01 Kymera Therapeutics Inc CDK2 compounds and their uses
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CA3223447A1 (en) 2021-06-25 2022-12-29 Korea Research Institute Of Chemical Technology Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof
WO2023076556A1 (en) 2021-10-29 2023-05-04 Kymera Therapeutics, Inc. Irak4 degraders and synthesis thereof
WO2023147594A2 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP2025513716A (ja) 2022-03-23 2025-04-30 ライジェル・ファーマシューティカルズ・インコーポレイテッド Ｉｒａｋ阻害剤としてのピリミド－２－イル－ピラゾール化合物
KR102607237B1 (ko) * 2023-06-07 2023-11-30 주식회사 젠센 신규한 트리아졸이 치환된 인다졸 유도체 및 이의 용도
WO2025036285A1 (zh) * 2023-08-11 2025-02-20 深圳众格生物科技有限公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1732004A (zh) * 2002-10-24 2006-02-08 细胞基因公司 用jnk抑制剂治疗疼痛
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
MX2007013383A (es) * 2005-04-29 2008-01-18 Celgene Corp Formas solidas de 1-(5-(1h-1,2,4-triazol-5-il)(1h-indazol-3-il))-3 -(2-piperidiletoxi)benceno.
WO2008154241A1 (en) * 2007-06-08 2008-12-18 Abbott Laboratories 5-heteroaryl substituted indazoles as kinase inhibitors

Also Published As

Publication number Publication date
KR20130133252A (ko) 2013-12-06
CN103429585A (zh) 2013-12-04
EA201300730A1 (ru) 2013-12-30
AU2011347711B2 (en) 2017-02-02
WO2012084704A1 (en) 2012-06-28
LT2655357T (lt) 2016-10-10
PL2655357T3 (pl) 2016-12-30
EP2655357B1 (en) 2016-06-22
AU2011347711A1 (en) 2013-08-01
US20130274241A1 (en) 2013-10-17
ES2592713T3 (es) 2016-12-01
SG191205A1 (en) 2013-07-31
HK1191938A1 (en) 2014-08-08
US9073892B2 (en) 2015-07-07
HRP20161127T1 (hr) 2016-11-18
RS55165B1 (sr) 2017-01-31
JP2014500286A (ja) 2014-01-09
PT2655357T (pt) 2016-09-28
CN103429585B (zh) 2015-07-08
HUE029617T2 (en) 2017-03-28
EA023544B1 (ru) 2016-06-30
IL226912A (en) 2017-01-31
BR122021014375B1 (pt) 2021-11-30
MX2013007149A (es) 2013-10-30
CA2822166C (en) 2019-10-29
BR112013015460A2 (pt) 2016-09-20
KR101842098B1 (ko) 2018-03-26
EP2655357A1 (en) 2013-10-30
BR112013015460B1 (pt) 2022-01-25
SI2655357T1 (sl) 2016-10-28
ZA201305483B (en) 2014-06-25
CA2822166A1 (en) 2012-06-28
JP6007189B2 (ja) 2016-10-12

Similar Documents

Publication Publication Date Title
AR084507A1 (es) Derivados de indazoliltriazol
AR080328A1 (es) Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
EA201490453A1 (ru) Замещенные аналоги (e)-n-(1-фенилэтилиден)бензогидразида в качестве ингибиторов деметилазы гистонов
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
AR087591A1 (es) Derivados de ciclohexil azetidina como inhibidores de jak
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
MX2018000179A (es) Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.
CU20130116A7 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
AR064010A1 (es) Inhibidores de la actividad de la akt
PE20110805A1 (es) Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR073480A1 (es) Benzamidas, su preparacion y su uso como medicamentos
AR084457A1 (es) Derivados de biciclo[3,2,1]octilamida
AR044829A1 (es) Derivados de bis-4-cloro fenil pirazinas
AR093725A1 (es) Quinazolincarboxamida azetidinas
AR072819A1 (es) Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
AR072518A1 (es) Derivados de imidazo [1,2-a]piridina, su procedimiento de preparacion, composiciones farmaceuticas y su utilizacion particularmente como inhibidores de met."
CU20090048A7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR081828A1 (es) Compuestos de biguanida y su uso para el tratamiento del cancer
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa

Legal Events

Date Code Title Description
FG Grant, registration